



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

In re Application of: :
DRUMM, et al. : Confirmation No. 9864
Serial No. 10/511,657 : Group Art Unit: 1635
Filed: April 18, 2005 : Examiner: Wollenberger, Louis V.

For: MEANS AND METHODS FOR THE SPECIFIC MODULATION OF
TARGET GENES IN THE CNS AND THE EYE AND METHODS FOR
THEIR IDENTIFICATION

Date Mailed: May 31, 2007

I HEREBY CERTIFY THAT THIS SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
VIA FIRST CLASS MAIL UNDER 37 CFR 1.8 AND IS ADDRESSED TO MAIL STOP
AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA
22313-1450

Kathleen Pujol
(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

Documents Mailed:
Information Disclosure Statement (2 pages)
Form PTO-1449 (2 pages)
References Cited (35)
Certificate of Mailing
Postcard

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DRUMM, et al.

Serial No. 10/511,657

Filed: April 18, 2005



:

:

:

:

Confirmation No. 9864

Group Art Unit: 1635

Examiner: Wollenberger, Louis V.

For: MEANS AND METHODS FOR THE SPECIFIC MODULATION OF
TARGET GENES IN THE CNS AND THE EYE AND METHODS FOR
THEIR IDENTIFICATION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

The undersigned asserts that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.



PATENT

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to Deposit Account No. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

A handwritten signature in black ink, appearing to read "Raymond A. Miller", with a long horizontal flourish extending to the right.

Raymond A. Miller
Registration No. 42,891

Pepper Hamilton LLP
500 Grant Street, 50th Floor
Pittsburgh, PA 15219
Telephone: (412) 454-5000
Facsimile: (412) 281-0717
Date: May 31, 2007



| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | | | | | |
|---|-------------|---|-------------------------|--|---|--|--|---|-------------------------|
| | | | | Application Number | | 10/511,657 | | | |
| | | | | Filing Date | | April 18, 2005 | | | |
| | | | | First Named Inventor | | Drumm | | | |
| | | | | Group Art Unit | | 1635 | | | |
| Examiner Name | | Wollenberger, Louis V. | | | | | | | |
| Sheet | 1 | of | 2 | Attorney Docket Number | | 129402.00201 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | |
| Examiner's Initials | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | | | |
| | | Number | Kind Code (if known) | | | | | | |
| ↓ | A1 | 2002/0054902 | A1 | Pardridge | 05-09-2002 | | | | |
| | A2 | 5,550,289 | A | Eppstein et al. | 08-27-1996 | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| Examiner's Initials | Cite No. | Foreign Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | | T | |
| | | Office | Number | | | | | | Kind Code (if known) |
| ↓ | B1 | WO | 98/48009 | A2 | University of Florida | 10-29-1998 | | | |
| | B2 | WO | 94/08026 | A1 | Rhone-Poulenc Rorer S.A. | 04-14-1994 | | | |
| | B3 | WO | 02/11666 | A2 | D-Pharm Ltd. | 02-14-2002 | | | |
| | B4 | WO | 99/12572 | A1 | University of Florida | 03-18-1999 | | | |
| | B5 | EP | 1229134 | A2 | Necleonics, Inc. et al. | 08-07-2002 | | | |
| | B6 | WO | 01/83729 | A | Novartis AG | 11-08-2001 | | | |
| | B7 | WO | 01/36646 | A | Cancer Res. Campaign Tech Lim | 05-25-2001 | | | |
| | B8 | WO | 00/44914 | A | Medical College of Georgia Research Institute | 08-03-2000 | | | |
| | B9 | WO | 02/088320 | A | University of Florida | 11-07-2002 | | | |
| OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | |
| Examiner's Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published. | | | | | | T | |
| ↓ | C1 | CARLSON et al., Perineurium in the Drosophila embryo and its role in the blood-brain/nerve barrier, 1998, Int. J. Insect Morphology and Embryology 27(2):61-66 | | | | | | | |
| | C2 | BANKS et al., Delivery across the blood-brain barrier of antisense directed against Amyloid beta: reversal of learning and memory deficits in mice overexpressing Amyloid precursor protein, 2001, J. Pharmacology and Experimental Therapeutics 297(3):1113-1121 | | | | | | | |
| | C3 | PARDRIDGE et al., Vector-mediated delivery of a polymamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo, 1995, Proc. Nat. Acad. Sci. USA 92:5592-5596 | | | | | | | |
| | C4 | BOADO et al., Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS, 1998, J. Pharm. Sci. 87(11):1308-1315 | | | | | | | |
| | C5 | TYLER et al., Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression, 1999, Proc. Natl. Acad. Sci. USA 96:7053-7058 | | | | | | | |
| | C6 | LEE et al., Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology, 2002, J. Nuclear Medicine 43(7):948-956 | | | | | | | |
| | C7 | PENICHERET et al., An antibody-Avidin fusion protein specific for the Transferrin Receptor serves as a delivery vehicle for the effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain, 1999, J. Immun. 163:4421-4426 | | | | | | | |
| | C8 | WU et al., Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system, 1996, J. Pharm. Exp. Ther. and Am. Soc. Pharm. 276(1):206-211 | | | | | | | |
| Examiner Signature | | | | Date Considered | | | | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



PATENT

| | | | | | |
|---|----------------------|---|---|--------------------------|-----------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/511,657 |
| | | | | Filing Date | April 18, 2005 |
| | | | | First Named Inventor | Drumm |
| | | | | Group Art Unit | 1635 |
| | | | | Examiner Name | Wollenberger, Louis V |
| Sheet | 2 | of | 2 | Attorney Docket Number | 129402.00201 |
| /L.W./ | C9 | SHI et al., Antisense imaging of gene expression in the brain in vivo, 2000, Proc. Natl. Acad. Sci. USA 97(26):14709-14714 | | | |
| | C10 | BOADO, Antisense drug delivery through the blood-brain barrier, 1995, Adv. Drug Delivery Reviews 15(1/3):73-107 | | | |
| | C11 | PINEDA et al., The genetic network of prototypic planarian eye regeneration is Pax6 independent, 2002, Development 129:1423-1434 | | | |
| | C12 | DRYJA et al., Mutations in the gene encoding the alpha subunit of the rod cGMP-gated channel in autosomal recessive retinitis pigmentosa, 1995, Proc. Natl. Acad. Sci. USA 92:10177-10181 | | | |
| | C13 | HUNT et al., Vitreous treatment of retinal pigment epithelial cells results in decreased expression of FGF-2, 1998, Investigative Ophthalmology & Visual Sci. 39(11):2111-2120 | | | |
| | C14 | KOCIOK et al., Vitreous treatment of cultured human RPE cells results in differential expression of 10 new genes, 2002, Investigative Ophthalmology & Visual Sci. 43(7):2474-2480 | | | |
| | C15 | CAMPOCHIARO, Gene therapy for retinal and choroidal diseases, 2002, Expert Opinion on Biological Therapy, 2(5):537-544 | | | |
| | C16 | KOCIOK et al., Upregulation of RAS-GTPase Activating Protein (GAP)-Binding Protein (G38BP) in proliferating RPE cells, 1999, J. Cellular Biochemistry 74:194-201 | | | |
| | C17 | CHAN et al., Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma, 2003, Ophthalmology 110(2):421-426 | | | |
| | C18 | AVGEROPOULOS et al., New treatment strategies for malignant gliomas, 1999, The Oncologist 4:209-224 | | | |
| | C19 | GROOTHUIS, The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery, 2000, Neuro-Oncology 2:45-59 | | | |
| | C20 | PARDRIDGE, Brain drug targeting and gene technologies, 2001, Japanese J. Pharmacology 87:97-103 | | | |
| | C21 | PARDRIDGE, Drug and gene targeting to the brain with molecular Trojan horses, 2002, Nature Reviews 1:131-139 | | | |
| | C22 | QIAN et al., Targeted drug delivery via the Transferrin Receptor mediated endocytosis pathway, 2002, Pharmacological Reviews 54(4):561-587 | | | |
| | C23 | PARDRIDGE, Vector-Mediated drug delivery to the brain, 1999, Advanced Drug Delivery Reviews, 36(2-3):299-321 | | | |
| | C24 | PARDRIDGE, CNS drug design based on principles of blood-brain barrier transport, 1998, J. Neurochemistry 70:1781-1792 | | | |
| | C25 | PARDRIDGE, Drug delivery to the brain, 1997, J. Cerebral Blood Flow and Metabolism, 17(7):713-731 | | | |
| | C26 | PHILIP et al., Polarized expression of monocarboxylate transporters in human retinal pigment epithelium and ARPE-19 cells, 2003, Investigative Ophthalmology & Visual Sci. 44(4):1716-1721 | | | |
| Examiner Signature | /Louis Wollenberger/ | | | Date Considered | 01/14/2008 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.